FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Dermatology Drugs in Phase II Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASN008

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2020

            Details:

            The results showed that a single application of ASN008 achieved a clinically meaningful reduction in pruritus of ? 4 points on the NRS in 2-3 hours.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EHP-101

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            EHP is currently initiating a Phase 2 clinical study for systemic sclerosis in Australia, New Zealand and the United States with EHP-101.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifx-1

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2020

            Details:

            Two out of the first five patients dosed with IFX-1 achieved complete remission. Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities in 3 dose cohorts.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Deuterated Ruxolitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            Oral JAK1/JAK2 Inhibitor CTP-543 achieves primary endpoint in patients with Alopecia Areata.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sofpironium Bromide

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 20, 2020

            Details:

            In this Phase 2b dose-finding study, sofpironium bromide elicited clinically and statistically significant sustained reductions in sweating severity and was well tolerated.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sofpironium Bromide

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Brickell Biotech

            Deal Size: $3.5 million Upfront Cash: $1.0 million

            Deal Type: Licensing Agreement February 18, 2020

            Details:

            The settlement resolves the previously disclosed dispute related to the sofpironium bromide license agreement allowing the Company to continue to produce sofpironium bromide to treat hyperhidrosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AUR101

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2020

            Details:

            The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human Rho D Immune Globulin

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2020

            Details:

            CSL Behring advances Ig clinical trial program to address need in treating serious autoimmune disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GLPG1690

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            With the NOVESA Phase 2 trial in SSc fully recruited, the company expects to see topline data in the second half of the year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Deuterated Ruxolitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            The CAFC’s grant of the Company’s motion will take effect on March 16, 2020 unless Incyte Corporation, which filed the petition for the IPR